<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535925</url>
  </required_header>
  <id_info>
    <org_study_id>246813579</org_study_id>
    <nct_id>NCT00535925</nct_id>
  </id_info>
  <brief_title>Nephropathy In Type 2 Diabetes and Cardio-renal Events</brief_title>
  <acronym>NID-2</acronym>
  <official_title>Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases:

      Phase 1(observational study, completed in September 2005): after the identification of a
      type-2 diabetic population with typical Diabetic Nephropathy (DN), to study of the rate of
      renal and cardiovascular events during a middle term follow-up.

      Phase 2(interventional study, started in October 2005): after randomization in two groups, a
      group (intervention group) is treated with an intensive multifactorial intervention whose aim
      is to reduce morbidity and mortality due to diabetic complications. The other group (control
      group) continues the conventional therapy . To avoid bias in the treatment in each center,
      the randomization was performed for centre.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The same patients that completed the first phase of the NID-2 study (observation) were
      enrolled for the phase 2 of the study (intervention).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2005</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)&quot;</measure>
    <time_frame>4 years (in the case the number of events needed by sample size is not reached at the expected 4-year time frame, primary end point will be assessed after the follow-up phase)</time_frame>
    <description>number of MACEs in the two groups are reported. In addition, The primary endpoint was analyzed with event curves for the time-to-first event based on Kaplan-Meier analysis. Cox regression model was used to calculate hazard ratio (HR) and 95% Confidence Interval (CI). Due to the cluster randomized study design, a Cox shared-frailty model was fitted. multivariable model was adjusted for selected potential confounders: age, sex, systolic blood pressure (SBP), hemoglobin, estimated glomerular filtration rate (eGFR), albuminuria, HbA1c, total cholesterol and triglycerides (log-scaled) to reduce risk of bias.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase&quot;</measure>
    <time_frame>13 years</time_frame>
    <description>Achievement of targets at end of intervention was performed applying generalized estimating equation (GEE) models, further adjusting for baseline values as covariate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">850</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SoC) therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.
In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (&lt;130/80 mmHg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SoC therapy</intervention_name>
    <description>the patients have to be treated according the standard good medical practice by any center</description>
    <arm_group_label>Standard of Care (SoC) therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irbesartan</intervention_name>
    <description>Therapy for hypertension:
- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramipril</intervention_name>
    <description>Therapy for hypertension:
- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide</intervention_name>
    <description>Therapy for hypertension
- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine &lt;2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>furosemide</intervention_name>
    <description>Therapy for hypertension
- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine &lt;2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>Therapy for hypertension
- Step 3: amlodipine up to 10 mg/die</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atenolol</intervention_name>
    <description>Therapy for hypertension
- Step 4: atenolol up to 100 mg/die</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxazosin</intervention_name>
    <description>Therapy for hypertension
- Step 5: doxazosin up to 4 mg/die</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clonidine</intervention_name>
    <description>Therapy for hypertension
- Step 6: clonidine</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin</intervention_name>
    <description>Therapy for Hyperglycaemia (to achieve HbA1c &lt;7):
- insulin</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Therapy for hypercholesterolemia:
- for reducing LDL cholesterol &lt; 100 mg/dl: simvastatin up to 80 mg/die</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fibrate</intervention_name>
    <description>Therapy for hypertriglyceridemia
- for reducing triglycerides &lt; 150 mg/dl and/or increasing HDL cholesterol &gt; 40-50 mg/dl: a fibrate</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>Treatment of anaemia:
- erythropoietin</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>Antiplatelet therapy (in all patients without contraindications):
- aspirin up to 160 mg/die</description>
    <arm_group_label>Multifactorial Intensified therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetic patients

          -  albumin extraction rate (AER= &gt;30 mg/die (micro- or macro-albuminuric ranges) in at
             least two determinations in the last six months

          -  diabetic retinopathy

          -  patients followed in the outpatients clinic for at least 12 months

        Exclusion Criteria:

          -  type 1 diabetic patients

          -  &lt;40 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferdinando C Sasso, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Università della Campania &quot;Luigi Vanvitelli&quot;, Naples, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Minutolo, MD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università della Campania &quot;Luigi Vanvitelli&quot;, Naples, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luca De Nicola, MD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Università della Campania &quot;Luigi Vanvitelli&quot;, Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Advanced Medical and Surgical Sciences, Università della Campania &quot;Luigi Vanvitelli&quot;, Naples, Italy</name>
      <address>
        <city>Naples</city>
        <zip>I-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Sasso FC, De Nicola L, Carbonara O, Nasti R, Minutolo R, Salvatore T, Conte G, Torella R. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care. 2006 Mar;29(3):498-503.</citation>
    <PMID>16505495</PMID>
  </reference>
  <reference>
    <citation>Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, Tirino G, Pota A, Torella R, Conte G, De Nicola L. Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens. 2006 Aug;24(8):1655-61.</citation>
    <PMID>16877970</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2007</study_first_posted>
  <results_first_submitted>April 28, 2020</results_first_submitted>
  <results_first_submitted_qc>April 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2020</results_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Ferdinando Carlo Sasso, MD, PhD</investigator_full_name>
    <investigator_title>AssociateProfessor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>nephropathy</keyword>
  <keyword>cardiovascular (CV) events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of patients originally enrolled in our study cohort, 538 patients with negative history of cardiovascular events were considered eligible and 111 further added from three new centers. 189 patients from 10 clinics were excluded prior to randomization due to their refusal to participate, 65 individuals due to change of either center or residence</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conventional Therapy</title>
          <description>Control group patients will continue their usual therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
current therapy: the patients have to be treated according the standard good medical practice by any center</description>
        </group>
        <group group_id="P2">
          <title>Intensified Therapy</title>
          <description>Intensive multifactorial intervention is performed to achieve goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia. New antihypertensive drugs will be added one by one until achievement of BP target (&lt;130/80 mmHg).
Therapy for Hypertension
Step1 - irbesartan 300 mg/die and ramipril 10 mg/die
Step 2 (Diuretic) - hydrochlorothiazide 12.5-25 mg/die, if creatinine &lt;2 mg/dL / furosemide 25-75 mg/die, if creatinine ≥2 mg/dL
Step 3 - amlodipine up to 10 mg/die
Step 4 - atenolol up to 100 mg/die
Step 5 - doxazosin up to 4 mg/die
Step 6 - Clonidine
Therapy for Hyperglycaemia (to achieve HbA1c &lt;7): insulin
Therapy for hypercholesterolemia (to reduce LDL &lt;100 mg/dl) --&gt; simvastatin till 80 mg/die
Therapy for hypertriglyceridemia (to reduce triglycerides &lt;150 mg/dl and/or increase HDL &gt;40-50 mg/dl) --&gt; fibrate
Treatment of anaemia: erythropoietin
Antiplatelets (all patients without contraindications): aspirin till 160 mg/die</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional Therapy</title>
          <description>Control group patients will continue their usual therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
current therapy: the patients have to be treated according the standard good medical practice by any center</description>
        </group>
        <group group_id="B2">
          <title>Intensified Therapy</title>
          <description>Intensive multifactorial intervention is performed to achieve goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia. New antihypertensive drugs will be added one by one until achievement of BP target (&lt;130/80 mmHg).
Therapy for Hypertension
Step1 - irbesartan 300 mg/die and ramipril 10 mg/die
Step 2 (Diuretic) - hydrochlorothiazide 12.5-25 mg/die, if creatinine &lt;2 mg/dL / furosemide 25-75 mg/die, if creatinine ≥2 mg/dL
Step 3 - amlodipine up to 10 mg/die
Step 4 - atenolol up to 100 mg/die
Step 5 - doxazosin up to 4 mg/die
Step 6 - Clonidine
Therapy for Hyperglycaemia (to achieve HbA1c &lt;7): insulin
Therapy for hypercholesterolemia (to reduce LDL &lt;100 mg/dl) --&gt; simvastatin till 80 mg/die
Therapy for hypertriglyceridemia (to reduce triglycerides &lt;150 mg/dl and/or increase HDL &gt;40-50 mg/dl) --&gt; fibrate
Treatment of anaemia: erythropoietin
Antiplatelets (all patients without contraindications): aspirin till 160 mg/die</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="188"/>
                    <count group_id="B2" value="207"/>
                    <count group_id="B3" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="188"/>
                    <count group_id="B2" value="207"/>
                    <count group_id="B3" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.2" spread="8.8"/>
                    <measurement group_id="B2" value="66.1" spread="9"/>
                    <measurement group_id="B3" value="67.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>number and percentage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="188"/>
                    <count group_id="B2" value="207"/>
                    <count group_id="B3" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="188"/>
                    <count group_id="B2" value="207"/>
                    <count group_id="B3" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>&quot;Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)&quot;</title>
        <description>number of MACEs in the two groups are reported. In addition, The primary endpoint was analyzed with event curves for the time-to-first event based on Kaplan-Meier analysis. Cox regression model was used to calculate hazard ratio (HR) and 95% Confidence Interval (CI). Due to the cluster randomized study design, a Cox shared-frailty model was fitted. multivariable model was adjusted for selected potential confounders: age, sex, systolic blood pressure (SBP), hemoglobin, estimated glomerular filtration rate (eGFR), albuminuria, HbA1c, total cholesterol and triglycerides (log-scaled) to reduce risk of bias.</description>
        <time_frame>4 years (in the case the number of events needed by sample size is not reached at the expected 4-year time frame, primary end point will be assessed after the follow-up phase)</time_frame>
        <population>number of MACEs reported will be at the end of the whole study period (follow-up) due to the fact that number needed to treat (NNT) at end of intervention was not reached)</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Therapy</title>
            <description>Control group patients will continue their usual therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
current therapy: the patients have to be treated according the standard good medical practice by any center</description>
          </group>
          <group group_id="O2">
            <title>Intensified Therapy</title>
            <description>Intensive multifactorial intervention is performed to achieve goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia. New antihypertensive drugs will be added one by one until achievement of BP target (&lt;130/80 mmHg).
Therapy for Hypertension
Step1 - irbesartan 300 mg/die and ramipril 10 mg/die
Step 2 (Diuretic) - hydrochlorothiazide 12.5-25 mg/die, if creatinine &lt;2 mg/dL / furosemide 25-75 mg/die, if creatinine ≥2 mg/dL
Step 3 - amlodipine up to 10 mg/die
Step 4 - atenolol up to 100 mg/die
Step 5 - doxazosin up to 4 mg/die
Step 6 - Clonidine
Therapy for Hyperglycaemia (to achieve HbA1c &lt;7): insulin
Therapy for hypercholesterolemia (to reduce LDL &lt;100 mg/dl) --&gt; simvastatin till 80 mg/die
Therapy for hypertriglyceridemia (to reduce triglycerides &lt;150 mg/dl and/or increase HDL &gt;40-50 mg/dl) --&gt; fibrate
Treatment of anaemia: erythropoietin
Antiplatelets (all patients without contraindications): aspirin till 160 mg/die</description>
          </group>
        </group_list>
        <measure>
          <title>&quot;Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)&quot;</title>
          <description>number of MACEs in the two groups are reported. In addition, The primary endpoint was analyzed with event curves for the time-to-first event based on Kaplan-Meier analysis. Cox regression model was used to calculate hazard ratio (HR) and 95% Confidence Interval (CI). Due to the cluster randomized study design, a Cox shared-frailty model was fitted. multivariable model was adjusted for selected potential confounders: age, sex, systolic blood pressure (SBP), hemoglobin, estimated glomerular filtration rate (eGFR), albuminuria, HbA1c, total cholesterol and triglycerides (log-scaled) to reduce risk of bias.</description>
          <population>number of MACEs reported will be at the end of the whole study period (follow-up) due to the fact that number needed to treat (NNT) at end of intervention was not reached)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox Shared Frailty Model, adjusted for age, sex, SBP, Hb, eGFR, albuminuria, HbA1c, total cholesterol, triglycerides (log-scaled) to reduce bias risk.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.48</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>&quot;Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase&quot;</title>
        <description>Achievement of targets at end of intervention was performed applying generalized estimating equation (GEE) models, further adjusting for baseline values as covariate.</description>
        <time_frame>13 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SoC) Therapy</title>
            <description>Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
SoC therapy: the patients have to be treated according the standard good medical practice by any center</description>
          </group>
          <group group_id="O2">
            <title>Multifactorial Intensified Therapy</title>
            <description>An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.
In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (&lt;130/80 mmHg).
Therapy for hypertension:
step 1: irbesartan 300 mg/die and ramipril 10 mg/die Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine &lt;2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl) Step 3: amlodipine up to 10 mg/die</description>
          </group>
        </group_list>
        <measure>
          <title>&quot;Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase&quot;</title>
          <description>Achievement of targets at end of intervention was performed applying generalized estimating equation (GEE) models, further adjusting for baseline values as covariate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 13 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Conventional Therapy</title>
          <description>Control group patients will continue their usual therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
current therapy: the patients have to be treated according the standard good medical practice by any center</description>
        </group>
        <group group_id="E2">
          <title>Intensified Therapy</title>
          <description>Intensive multifactorial intervention is performed to achieve goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia. New antihypertensive drugs will be added one by one until achievement of BP target (&lt;130/80 mmHg).
Therapy for Hypertension
Step1 - irbesartan 300 mg/die and ramipril 10 mg/die
Step 2 (Diuretic) - hydrochlorothiazide 12.5-25 mg/die, if creatinine &lt;2 mg/dL / furosemide 25-75 mg/die, if creatinine ≥2 mg/dL
Step 3 - amlodipine up to 10 mg/die
Step 4 - atenolol up to 100 mg/die
Step 5 - doxazosin up to 4 mg/die
Step 6 - Clonidine
Therapy for Hyperglycaemia (to achieve HbA1c &lt;7): insulin
Therapy for hypercholesterolemia (to reduce LDL &lt;100 mg/dl) --&gt; simvastatin till 80 mg/die
Therapy for hypertriglyceridemia (to reduce triglycerides &lt;150 mg/dl and/or increase HDL &gt;40-50 mg/dl) --&gt; fibrate
Treatment of anaemia: erythropoietin
Antiplatelets (all patients without contraindications): aspirin till 160 mg/die</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="188"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="188"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>revascularization</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>major amputation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>if systolic blood pressure &lt;= 100 mmHg</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>if fasting glycemia &lt;= 70 mg/dL</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>End Stage Renal Disease</sub_title>
                <description>if eGFR (CKD-EPI) &lt; 15 ml/min</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Ferdinando Carlo Sasso. MD, PhD</name_or_title>
      <organization>University of Campania</organization>
      <phone>+39-081-5665010</phone>
      <email>ferdinandocarlo.sasso@unicampania.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

